News und Analysen
Vifor Pharma comments on market speculations
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Due to current market speculations, Vifor Pharma Group states the following:
Vifor Pharma Group systematically reviews options that
LivaNova to Present Scientific Data on VNS Therapy for Drug-Resistant Epilepsy at American Epilepsy Society 2021 Annual Meeting
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) Annual Meeting taking place December
Simulations Plus Extends its Distributor Agreement in Japan with Northern Science Consulting for Monolix™
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has extended its
Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress
IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and blood cancers, today announced
ABIONYX Announces the Success of Its Capital Increase in Cash by Private Placement at a Price of €3.60 Per Share
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for
QIAGEN Launches CE-marked Version of QuantiFERON® SARS-CoV-2 to Assess T-cell Response to COVID-19
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the CE marking of its QuantiFERON® SARS-CoV-2 assay that measures T-cell responses to SARS-CoV-2 and aids in the assessment
QIAGEN lanciert CE-gekennzeichnete Version des QuantiFERON® SARS-CoV-2 Tests zur Bestimmung der T-Zell-Reaktion auf COVID-19
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die CE-Kennzeichnung seines QuantiFERON® SARS-CoV-2 Tests bekannt, der die T-Zell-Reaktion auf SARS-CoV-2 nachweisen und den
Chemed Corporation to Present at the BofA Securities 2021 Virtual Home Care Conference
Chemed Corporation (NYSE:CHE) today announced that it will present at the BofA Securities 2021 Virtual Home Care Conference on Tuesday, December 7, 2021, at 11:00 AM (ET).
The presentation will
Valbiotis meldet die Einreichung von drei klinischen Protokollen für den zur Blutdrucksenkung indizierten Wirkstoff TOTUM•854 bei den zuständigen Behörden und stellt seinen Plan für eine umfassende klinische Entwicklung vor
Pflichtmeldung:
Valbiotis (FR0013254851 – ALVAL, PEA/SME-qualifiziert) (Paris:AVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation
Orlando Health Forms Joint Venture With Acadia Healthcare to Expand Behavioral Health Services in the Region
Orlando Health and Acadia Healthcare Company announced today that they have formed a joint venture designed to enhance and expand behavioral health services in the region.
This press release
Acadia Healthcare Forms Joint Venture With Orlando Health
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it has formed a joint venture with Orlando Health, one of Central Florida’s premier health systems. With Acadia’s partnership
EQS-Adhoc: Veränderung im Verwaltungsrat von Newron
DGAP-Adhoc: Veränderung im Verwaltungsrat von Newron
LivaNova to Present Scientific Data on VNS Therapy for Difficult-to-Treat Depression at 4th International Brain Stimulation Conference
LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its participation in the 4th International Brain Stimulation Conference, taking place
PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth
Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”)
Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:AVAL), a Research and Development company committed to scientific innovation for preventing and combating metabolic and
GenSight Biologics Announces Publication of Non-Human Primate Study Reporting Presence of LUMEVOQ® Vector DNA in Contralateral Eyes After Unilateral Injection
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
DGAP-News: Fresenius Medical Care AG & Co. KGaA passt Besetzung des Vorstands an neues Betriebsmodell an
DGAP-News: Fresenius Medical Care AG & Co. KGaA announces changes to Management Board, reflecting the transformation to the company's new operating model
Quidel Statement on the Omicron Variant
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement from
Loudoun Medical Group Joins Humana Medicare Advantage Network
Loudoun Medical Group, P.C. (LMG), one of the largest and most diverse physician-owned, multi-specialty group practices in Virginia, and leading health and well-being company Humana Inc. (NYSE
AMN Healthcare CEO Susan Salka Named to Global Power 150 – Women in Staffing for Seventh Consecutive Year
Susan Salka, President and CEO of AMN Healthcare (NYSE: AMN), has been named to the 2021 Global Power 150 – Women in Staffing by Staffing Industry Analysts for the seventh consecutive year.
The
Simulations Plus Celebrates 25-Year Anniversary with $25,000 Gift to Nonprofit, Dispensary of Hope
Simulations Plus, Inc. (Nasdaq: SLP) is celebrating 25 years in business and continuing the commitment to improve public health through innovative solutions with a $25,000 donation to the
Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commercial Operations
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today announced a corporate